A Discussion on oHCM: Part 4 – How Pharmacists Drive Earlier Intervention, Long-Term Mavacamten Success

In the final part of an interview with Pharmacy Times, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, a cardiovascular clinical pharmacist with Baptist Health System and the University of Kentucky College of Pharmacy, issued a broad call to action for pharmacists across all practice settings—not just those working in cardiology clinics—to engage with obstructive hypertrophic cardiomyopathy (oHCM) management and position themselves as active contributors to patient care.

Beavers outlined 3 domains of pharmacist engagement. The first is continuous education: understanding the distinction between obstructive and nonobstructive HCM, staying current on drug interactions, and following patients' clinical trajectories regardless of practice setting. The second is patient advocacy: proactively screening for drug interactions, monitoring adherence, and ensuring patients on cardiac myosin inhibitor therapy are following up appropriately—responsibilities he emphasized belong to every pharmacist who encounters these patients, whether in a specialty clinic or a community pharmacy.

The third is care integration: seeking opportunities to formally embed into oHCM care teams through collaborative practice agreements and other mechanisms, taking on titration and management responsibilities that reduce the burden on other providers.

Regarding mavacamten's (Camzyos; Bristol Myers Squibb) long-term sustainability as a therapy, Beavers described the convergence of clinical trial data and real-world Risk Evaluation and Mitigation Strategy outcomes as mutually reinforcing. Clinical trials established early proof of efficacy, whereas real-world data answer the longer-term safety questions that trials cannot sustain indefinitely. Critically, he noted that the real-world data show outcomes are consistent when prescribing protocols are followed, validating not just the drug but the monitoring framework built around it.

Beavers closed by reiterating what he called the most foundational point of the entire conversation: pharmacists must understand the difference between obstructive and nonobstructive HCM before engaging in management, ensuring their interventions are appropriately matched to what the patient actually has.